What are the second-line and subsequent treatment regimens for diffuse large B-cell lymphoma (DLBCL)?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Second-line and subsequent therapy (intention to proceed to high-dose therapy) regimens are as follows:

  • DHAP (dexamethasone, high-dose cytarabine [Ara-C], cisplatin [Platinol]) ± rituximab
  • ESHAP (etoposide, methylprednisolone [Solu-Medrol], high-dose cytarabine, cisplatin) ± rituximab
  • GDP (gemcitabine, dexamethasone, cisplatin or carboplatin) ± rituximab
  • GemOx (gemcitabine, oxaliplatin) ± rituximab
  • ICE (ifosfamide, carboplatin, etoposide) ± rituximab
  • MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!